Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

SIGA vs RIGL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RIGL Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

RIGL Overall Winner 6-Pillar Tally: SIGA 2 – 4 RIGL Matrix Metrics: SIGA 2 – 8 RIGL

As of Nov 19, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SIGA carries a Unified Composite Score of 47.5/100 (HOLD) at $2.65 (2.5x Forward P/E, -14.2% operating margin), whereas RIGL carries 61.3/100 (BUY) at $41.19 (8.6x Forward P/E, 26.3% operating margin).

  • Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SIGA vs RIGL
SIGA NASDAQ
SIGA Technologies Inc.
Pharmaceutical Preparations
$2.65
-5.36% 1D
Market Cap $187.9M
TTM Revenue $52M
Forward P/E 2.5x
Beta / 30D Vol 0.75β · 65% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.7%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $3.02 · SMA50: $3.14
RIGL NASDAQ Head-to-Head Winner
Rigel Pharmaceuticals Inc. (New)
Pharmaceutical Preparations
$41.19
-3.15% 1D
Market Cap $800.8M
TTM Revenue $288M
Forward P/E 8.6x
Beta / 30D Vol 1.06β · 72% Vol
Unified Composite Score
61.3 / 100 BUY
Tech 50.0 Fund 63.0 Flow 67.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.9 · SMA20: $46.47 · SMA50: $47.04

6-Pillar Scorecard Institutional Category Breakdown (SIGA 2 – 4 RIGL)

Columns: Metric · SIGA · RIGL
1. Valuation Multiples SIGA
Forward P/E 2.5x 8.6x
Trailing P/E N/M 2.6x
PEG Ratio 3.37x N/M
EV / Revenue 1.4x 2.6x
2. Growth & Scale RIGL
Revenue Growth (YoY) -49.7% +16.5%
Earnings Growth (YoY) -65.3% -55.5%
TTM Revenue (USD) $52M $288M
Market Cap $187.9M $800.8M
3. Profitability & Quality RIGL
Gross Margin 23.4% 70.7%
Operating Margin -14.2% 26.3%
Net Profit Margin 1.3% 106.6%
Return on Equity (ROE) 0.4% 109.2%
4. Balance Sheet & Cash Flow RIGL
Cash Generation (TTM) -$12M $19M
Cash Flow Margin -22.1% 6.7%
Net Cash / Leverage $116M Net Cash $39M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SIGA
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 81.4% (8th %ile) 69.0% (5th %ile)
Put/Call OI Skew 0.04x (Call-Skewed) 0.03x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat RIGL
OpEx & R&D Intensity 37.6% of Rev ($20M) 44.4% of Rev ($128M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SIGA (2) vs RIGL (8)
Institutional Metric SIGA RIGL Criterion Row Edge
Market Capitalization
Scale
$187.9M $800.8M Larger Scale RIGL
Trailing P/E Ratio
Valuation
N/M 2.6x Lower Multiple RIGL
Forward P/E Ratio
Valuation
2.5x 8.6x Lower Multiple SIGA
Revenue Growth (YoY)
Growth
-49.7% +16.5% Higher Growth RIGL
Operating Margin (TTM)
Profitability
-14.2% 26.3% Higher Margin RIGL
Net Profit Margin
Profitability
1.3% 106.6% Higher Margin RIGL
Return on Equity (ROE)
Capital Efficiency
0.4% 109.2% Higher ROE RIGL
52-Week Range Position
Momentum
3% ($3–$7) 59% ($25–$53) Stronger Trend RIGL
Beta / 30D Volatility
Risk Regime
0.75β · 65% Vol 1.06β · 72% Vol Lower Realized Risk SIGA
Unified Institutional Score
Composite Signal
47.5 / 100 (HOLD) 61.3 / 100 (BUY) Higher Composite RIGL
Trailing 12M Revenue (USD)
Operating Scale
$52M $288M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.4% 70.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.37x PEG · 1.4x EV/Rev N/M PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M ($116M Net Cash) $19M ($39M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SIGA +0.67 pp
SIGA: -15.06% · RIGL: -15.73%
3M Horizon RIGL +2.59 pp
SIGA: -12.83% · RIGL: -10.24%
6M Horizon RIGL +84.85 pp
SIGA: -43.74% · RIGL: +41.11%
1Y Horizon RIGL +44.73 pp
SIGA: -55.61% · RIGL: -10.88%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SIGA Revenue RIGL Revenue SIGA Op. Margin RIGL Op. Margin Margin Leader
FY2018 $480M $40M 74.4% -163.3% SIGA
FY2019 $30M $60M -8.7% -116.5% SIGA
FY2020 $120M $110M 67.6% -26.7% SIGA
FY2021 $130M $150M 66.7% -8.4% SIGA
FY2022 $110M $120M 38.5% -46.2% SIGA
FY2023 $140M $120M 59.8% -17.5% SIGA
FY2024 $140M $180M 50.4% 13.5% SIGA
FY2025 $90M $290M 25.1% 42.6% RIGL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SIGA CONSOLIDATION
33d in phase · OBV DISTRIBUTION
Current IV 81.4%
IV Percentile 8th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIGA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RIGL CONSOLIDATION
94d in phase · OBV NEUTRAL
Current IV 69.0%
IV Percentile 5th %ile
Put/Call OI Skew 0.03x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RIGL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SIGA Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $187.9M market capitalization and -14.2% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($20M)
90D Engineering Disclosures 0 Published
RIGL Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $800.8M market capitalization and 26.3% operating margin.
OpEx & R&D Reinvestment 44.4% of Rev ($128M)
90D Engineering Disclosures 0 Published

Investor FAQ SIGA vs RIGL Key Questions & Quantitative Answers

As of Nov 19, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SIGA carries a Unified Composite Score of 47.5/100 (HOLD) at $2.65 (2.5x Forward P/E, -14.2% operating margin), whereas RIGL carries 61.3/100 (BUY) at $41.19 (8.6x Forward P/E, 26.3% operating margin). Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RIGL leads the Growth & Scale pillar: SIGA posts -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin), compared with RIGL at +16.5% YoY revenue growth and -55.5% YoY earnings growth on $288M TTM revenue (70.7% gross margin, 26.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SIGA cumulative revenue shifted -81.2% while RIGL shifted +625.0%. In operating R&D and SG&A reinvestment, SIGA deploys 37.6% of Rev ($20M) (0 90-day corporate R&D disclosures) versus 44.4% of Rev ($128M) (0 disclosures) for RIGL.

SIGA screens cheaper on headline valuation multiples. SIGA trades at 2.5x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin), whereas RIGL trades at 8.6x Forward P/E, 2.6x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (6.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SIGA (0.4% ROE) versus RIGL (109.2% ROE) capital efficiency.

In options market volatility and institutional positioning, SIGA carries 81.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 65% Vol realized risk). By comparison, RIGL carries 69.0% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.03x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.06β · 72% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.